The United States has granted tariff exemptions on specific specialized pharmaceuticals and raw materials imported from Bangladesh.

The measure forms part of a broader tariff relief initiative extended to 20 countries for medications utilized in treating rare and complex diseases.

According to a report by NDTV on Tuesday (September 29), the exemptions apply to imports from 20 nations and customs territories, including Bangladesh, India, Argentina, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, the United Kingdom, and Vietnam.

Scope of the Tariff Exemptions
Under the U.S. Department of Commerce guidelines, zero-tariff benefits apply to medications designated for rare diseases, fertility treatments, cell-based therapies, and gene therapies, alongside the primary raw materials required for their manufacture.

These exemptions are part of the implementation of the April proclamation issued by U.S. President Donald Trump regarding the adjustment of pharmaceutical and raw material imports under Section 232 of the Trade Expansion Act.

While the proclamation generally initiates 100 percent tariffs on certain patented pharmaceuticals and related components effective September 29, the Department of Commerce has carved out exemptions for qualifying partner countries.

Key Regulatory Clarifications
Strategic Framework: The Department of Commerce noted that these tariff waivers are granted based on current or upcoming trade and security frameworks between the United States and the respective countries.

Exclusion of Generics: Generic drugs and their corresponding ingredients fall outside the scope of the Section 232 pharmaceutical tariffs.

Technical Amendments: Recent regulatory updates include a revised definition of "generic pharmaceutical materials" to explicitly incorporate unpatented animal health products.

Furthermore, the Department clarified that "pharmaceutical materials" strictly cover finished medications, their active pharmaceutical ingredients (APIs), and the foundational raw materials used to produce those ingredients.